Dr. Tabas, Richard J. Stock Professor of Medicine, Columbia University, completed his M.D./Ph.D. at Washington University and his clinical training at Columbia. His research has focused on the integrated area of cardiometabolic disease, where he has elucidated signaling pathways in macrophages that contribute to atherosclerosis and in hepatocytes that contribute to type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). His papers have appeared in Cell, Nature, Science, Nature Cell Biology, Cell Metabolism, Journal of Clinical Investigation, PNAS, and other top journals, and he is on Science’s Board of Reviewing Editors.
Dr. Tabas has patents related to both atherosclerosis and T2D therapy, and he is co-founder of Tabomedex Biosciences, which is developing drugs for T2D and atherosclerosis. His awards include election to ASCI/AAP; AHA Established Investigator Award; Columbia University Lamport Award; AHA/ATVB Council Special Recognition Award; Washington University Alumni Achievement Award; Society of Leukocyte Biology Bonazinga award, which is the society’s highest honor for excellence in leukocyte biology research; Harrington Discovery Institute Innovator-Scholar Award; the AHA Ross Lectureship Award; 2019 NHLBI Outstanding Investigator Award; Keynote lecturer for the 2019 Gordon Research Conference on Phagocytosis; 2019 Dean’s Distinguish Lecture, Columbia University Medical Center; 2019 Hugh Sinclair Memorial Lecture, British Atherosclerosis Society; and 2020 Journal of Lipid Research Award Lecture, Deuel Conference on Lipids. The lab has been supported by multiple NIH R01/P01 grants without interruption for the last 30 years, including a recent R35 Outstanding Investigator Award from the NHLBI.